Nanotechnologies for Supramolecular Design in Medicine:
To build a high value biotechnology company MSI believes that each sentinel clinical trial should greatly reduce the risk of a pipeline of following products. By committing itself to development expertise and intellectual property strength in platform technologies, MSI intends to follow each clinical trial success with similar products.
Staged Development/Regulatory Risk
The development program includes products with three classes of development risk. The lead product is its brachytherapy catheter - a medical device with good prospects for FDA 510K compatibility. This is expected to generate early income with comparatively low regulatory risk.
The second line of products is in the MRI image contrast arena. This is a pharmaceutical requiring full scale clinical trials. However, efficacy is achieved simply by delivering the agent to the blood stream with low toxicity, so the regulatory risk is limited.
The third line of products is for intraneural drug delivery. These face a relatively high regulatory risk for toxicity testing and efficacy, however each product will revolutionize medical therapy for a very large high value market - pain, muscle spasm, viral nerve infection, neuroprotection.
Early Progress to Clinical Trials
To rapidly grow the value of the company, the MSI technologies have been staged to prepare lead products in each category to enter the FDA approval processes within 18 months with a stream of additional products entering the trial process in subsequent years.
MSI has assembled a world class team of advisors with extensive experience in developing new products and pharmaceuticals in its three major develoment areas of catheter devices, image contrast agents, and pain medication.